Zobrazeno 1 - 10
of 345
pro vyhledávání: '"Olaf Neumann"'
Autor:
Andreas Mock, Maria-Veronica Teleanu, Simon Kreutzfeldt, Christoph E. Heilig, Jennifer Hüllein, Lino Möhrmann, Arne Jahn, Dorothea Hanf, Irina A. Kerle, Hans Martin Singh, Barbara Hutter, Sebastian Uhrig, Martina Fröhlich, Olaf Neumann, Andreas Hartig, Sascha Brückmann, Steffen Hirsch, Kerstin Grund, Nicola Dikow, Daniel B. Lipka, Marcus Renner, Irfan Ahmed Bhatti, Leonidas Apostolidis, Richard F. Schlenk, Christian P. Schaaf, Albrecht Stenzinger, Evelin Schröck, Daniel Hübschmann, Christoph Heining, Peter Horak, Hanno Glimm, Stefan Fröhling
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-15 (2023)
Abstract Analysis of selected cancer genes has become an important tool in precision oncology but cannot fully capture the molecular features and, most importantly, vulnerabilities of individual tumors. Observational and interventional studies have s
Externí odkaz:
https://doaj.org/article/47ffdc7c0d55467aa0a4083d56bfaa6d
Autor:
Michael Menzel, Stephan Ossowski, Sebastian Kral, Patrick Metzger, Peter Horak, Ralf Marienfeld, Melanie Boerries, Steffen Wolter, Markus Ball, Olaf Neumann, Sorin Armeanu-Ebinger, Christopher Schroeder, Uta Matysiak, Hannah Goldschmid, Vincent Schipperges, Axel Fürstberger, Michael Allgäuer, Timo Eberhardt, Jakob Niewöhner, Andreas Blaumeiser, Carolin Ploeger, Tobias Bernd Haack, Timothy Kwang Yong Tay, Olga Kelemen, Thomas Pauli, Martina Kirchner, Klaus Kluck, Alexander Ott, Marcus Renner, Jakob Admard, Axel Gschwind, Silke Lassmann, Hans Kestler, Falko Fend, Anna Lena Illert, Martin Werner, Peter Möller, Thomas Theodor Werner Seufferlein, Nisar Malek, Peter Schirmacher, Stefan Fröhling, Daniel Kazdal, Jan Budczies, Albrecht Stenzinger
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-11 (2023)
Abstract A growing number of druggable targets and national initiatives for precision oncology necessitate broad genomic profiling for many cancer patients. Whole exome sequencing (WES) offers unbiased analysis of the entire coding sequence, segmenta
Externí odkaz:
https://doaj.org/article/c80cfb96a9be48f6bbb8329e92275143
Autor:
Olaf Neumann, Ulrich Lehmann, Stephan Bartels, Nicole Pfarr, Thomas Albrecht, Katharina Ilm, Jens Christmann, Anna‐Lena Volckmar, Hannah Goldschmid, Martina Kirchner, Michael Allgäuer, Maria Walker, Hans Kreipe, Andrea Tannapfel, Wilko Weichert, Peter Schirmacher, Daniel Kazdal, Albrecht Stenzinger
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 9, Iss 2, Pp 100-107 (2023)
Abstract Intrahepatic cholangiocarcinoma harbours druggable genetic lesions including FGFR2 gene fusions. Reliable and accurate detection of these fusions is becoming a critical component of the molecular work‐up, but real‐world data on the perfo
Externí odkaz:
https://doaj.org/article/766fefd6743746f48f23bf3da053da40
Autor:
Michael Menzel, Volker Endris, Constantin Schwab, Klaus Kluck, Olaf Neumann, Susanne Beck, Markus Ball, Christian Schaaf, Stefan Fröhling, Peter Lichtner, Peter Schirmacher, Daniel Kazdal, Albrecht Stenzinger, Jan Budczies
Publikováno v:
Translational Oncology, Vol 35, Iss , Pp 101706- (2023)
Homologous recombination deficiency (HRD) is a predictive marker for response to poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian carcinoma. HRD scores have entered routine diagnostics, but the influence of algorithms, parameters and confou
Externí odkaz:
https://doaj.org/article/4e88daf2b11f4936876a9802128bc881
Autor:
Karl-Heinz Schlote, Peter Ullrich
Publikováno v:
NTM International Journal of History and Ethics of Natural Sciences, Technology and Medicine. 12:117-120
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::734da100189a5c5eb7256921bf82764d
https://doi.org/10.1007/bf03004135
https://doi.org/10.1007/bf03004135
Autor:
Florian P, Reiter, Monika, Rau, Volker, Kunzmann, Ralph, Kickuth, Ingo, Klein, Olaf, Neumann, Albrecht, Stenzinger, Peter, Schirmacher, Andreas, Geier
Publikováno v:
Zeitschrift für Gastroenterologie. 61:71-75
Immunotherapy has become the standard of care in advanced HCC but is only approved in first- or second-line treatment. We report a patient with HCC refractory to several lines of tyrosine kinase inhibitors, who was treated with Ipilimumab and Nivolum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3b1ec4d3c5b71d92957beabaf02832c
https://doi.org/10.1055/a-1952-1233
https://doi.org/10.1055/a-1952-1233
Autor:
Stefan Fröhling, Hanno Glimm, Wilko Weichert, Daniel Hübschmann, Evelin Schröck, Albrecht Stenzinger, Benedikt Brors, Barbara Klink, Christof von Kalle, Klaus Schulze-Osthoff, Michael Bitzer, Karsten Spiekermann, Philipp J. Jost, Nikolas von Bubnoff, Anna L. Illert, Melanie Boerries, Thomas Kindler, Christian H. Brandts, Jens Thomas Siveke, Sebastian Bauer, Gunnar Folprecht, Frederick Klauschen, Ulrich Keilholz, Richard F. Schlenk, Peter Schirmacher, Matthias Kroiss, Peter Hohenberger, Walter E. Aulitzky, Marinela Augustin, Ivo Buchhalter, Bettina Meißburger, Christina Geörg, Katrin Pfütze, Stephan Wolf, Ulrike Winter, Daniela Richter, Katja Beck, Roland Penzel, Olaf Neumann, Volker Endris, Andreas Laßmann, Leo Ruhnke, Michael Allgäuer, Daniel B. Lipka, Christoph E. Heilig, Veronica Teleanu, Dorothea Hanf, Lino Möhrmann, Laura Gieldon, Andreas Rump, Arne Jahn, Sebastian Uhrig, Martina Fröhlich, Jennifer Hüllein, Andreas Mock, Barbara Hutter, Simon Kreutzfeldt, Christoph Heining, Peter Horak
This file contains supplementary figures S1-S10.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78cc54fe18039002f33117343da90145
https://doi.org/10.1158/2159-8290.22540594
https://doi.org/10.1158/2159-8290.22540594
Autor:
Stefan Fröhling, Hanno Glimm, Wilko Weichert, Daniel Hübschmann, Evelin Schröck, Albrecht Stenzinger, Benedikt Brors, Barbara Klink, Christof von Kalle, Klaus Schulze-Osthoff, Michael Bitzer, Karsten Spiekermann, Philipp J. Jost, Nikolas von Bubnoff, Anna L. Illert, Melanie Boerries, Thomas Kindler, Christian H. Brandts, Jens Thomas Siveke, Sebastian Bauer, Gunnar Folprecht, Frederick Klauschen, Ulrich Keilholz, Richard F. Schlenk, Peter Schirmacher, Matthias Kroiss, Peter Hohenberger, Walter E. Aulitzky, Marinela Augustin, Ivo Buchhalter, Bettina Meißburger, Christina Geörg, Katrin Pfütze, Stephan Wolf, Ulrike Winter, Daniela Richter, Katja Beck, Roland Penzel, Olaf Neumann, Volker Endris, Andreas Laßmann, Leo Ruhnke, Michael Allgäuer, Daniel B. Lipka, Christoph E. Heilig, Veronica Teleanu, Dorothea Hanf, Lino Möhrmann, Laura Gieldon, Andreas Rump, Arne Jahn, Sebastian Uhrig, Martina Fröhlich, Jennifer Hüllein, Andreas Mock, Barbara Hutter, Simon Kreutzfeldt, Christoph Heining, Peter Horak
This excel file contains supplementary tables S1-S7.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e428080e402d523c04319eabcfe5d70
https://doi.org/10.1158/2159-8290.22540588.v1
https://doi.org/10.1158/2159-8290.22540588.v1
Autor:
Stefan Fröhling, Hanno Glimm, Wilko Weichert, Daniel Hübschmann, Evelin Schröck, Albrecht Stenzinger, Benedikt Brors, Barbara Klink, Christof von Kalle, Klaus Schulze-Osthoff, Michael Bitzer, Karsten Spiekermann, Philipp J. Jost, Nikolas von Bubnoff, Anna L. Illert, Melanie Boerries, Thomas Kindler, Christian H. Brandts, Jens Thomas Siveke, Sebastian Bauer, Gunnar Folprecht, Frederick Klauschen, Ulrich Keilholz, Richard F. Schlenk, Peter Schirmacher, Matthias Kroiss, Peter Hohenberger, Walter E. Aulitzky, Marinela Augustin, Ivo Buchhalter, Bettina Meißburger, Christina Geörg, Katrin Pfütze, Stephan Wolf, Ulrike Winter, Daniela Richter, Katja Beck, Roland Penzel, Olaf Neumann, Volker Endris, Andreas Laßmann, Leo Ruhnke, Michael Allgäuer, Daniel B. Lipka, Christoph E. Heilig, Veronica Teleanu, Dorothea Hanf, Lino Möhrmann, Laura Gieldon, Andreas Rump, Arne Jahn, Sebastian Uhrig, Martina Fröhlich, Jennifer Hüllein, Andreas Mock, Barbara Hutter, Simon Kreutzfeldt, Christoph Heining, Peter Horak
This file contains supplementary methods and references.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::435481f4972c62a123612684848756ea
https://doi.org/10.1158/2159-8290.22540591
https://doi.org/10.1158/2159-8290.22540591
Autor:
Stefan Fröhling, Hanno Glimm, Wilko Weichert, Daniel Hübschmann, Evelin Schröck, Albrecht Stenzinger, Benedikt Brors, Barbara Klink, Christof von Kalle, Klaus Schulze-Osthoff, Michael Bitzer, Karsten Spiekermann, Philipp J. Jost, Nikolas von Bubnoff, Anna L. Illert, Melanie Boerries, Thomas Kindler, Christian H. Brandts, Jens Thomas Siveke, Sebastian Bauer, Gunnar Folprecht, Frederick Klauschen, Ulrich Keilholz, Richard F. Schlenk, Peter Schirmacher, Matthias Kroiss, Peter Hohenberger, Walter E. Aulitzky, Marinela Augustin, Ivo Buchhalter, Bettina Meißburger, Christina Geörg, Katrin Pfütze, Stephan Wolf, Ulrike Winter, Daniela Richter, Katja Beck, Roland Penzel, Olaf Neumann, Volker Endris, Andreas Laßmann, Leo Ruhnke, Michael Allgäuer, Daniel B. Lipka, Christoph E. Heilig, Veronica Teleanu, Dorothea Hanf, Lino Möhrmann, Laura Gieldon, Andreas Rump, Arne Jahn, Sebastian Uhrig, Martina Fröhlich, Jennifer Hüllein, Andreas Mock, Barbara Hutter, Simon Kreutzfeldt, Christoph Heining, Peter Horak
The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the Germa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c93807e7be6f392f20432b51be5abfb
https://doi.org/10.1158/2159-8290.c.6549421
https://doi.org/10.1158/2159-8290.c.6549421